Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report)'s share price traded up 10.4% on Friday . The stock traded as high as $8.54 and last traded at $8.51. 207,627 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,558,064 shares. The stock had previously closed at $7.71.
Analyst Ratings Changes
A number of brokerages have weighed in on VERV. HC Wainwright cut their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group raised their target price on Verve Therapeutics from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada dropped their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th.
View Our Latest Report on VERV
Verve Therapeutics Stock Performance
The firm's 50 day moving average is $6.70 and its 200-day moving average is $5.92. The firm has a market cap of $717.92 million, a price-to-earnings ratio of -3.45 and a beta of 1.74.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its position in shares of Verve Therapeutics by 189.7% during the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after purchasing an additional 3,964 shares during the last quarter. IFP Advisors Inc boosted its holdings in Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after purchasing an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Verve Therapeutics in the fourth quarter valued at $50,000. Creative Planning bought a new stake in shares of Verve Therapeutics in the 3rd quarter worth about $50,000. Finally, PFG Investments LLC bought a new stake in Verve Therapeutics during the third quarter worth about $53,000. 97.11% of the stock is owned by institutional investors.
Verve Therapeutics Company Profile
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Read More
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
